APLS vs XEL · rev $1.00B vs P/E 20, $39.33B cap
Apellis Pharmaceuticals Inc (APLS) versus Xcel Energy Inc (XEL) — a side-by-side from cached financials, not a winner call.
Apellis Pharmaceuticals Inc (APLS) is a biotechnology company listed on US.
Xcel Energy Inc (XEL) is a utilities - regulated electric company listed on US.
Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.
XEL does not have a complete income-statement cache yet.
APLS currently screens at market cap $2.29B. XEL currently screens at market cap $39.33B and trailing P/E 20.1.
Not investment advice. Open the APLS and XEL stock pages for the full models.
Not investment advice.